SCHEMBL23175993

SCHEMBL23175993

O=C(CCl)N(Cc1ccccc1)C1CCCCC1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AGER Q15109 3/20 0.63
NPC1 O15118 2/20 0.60
ALDH1A1 P00352 2/20 0.60
RAB9A P51151 2/20 0.60
PAX8 Q06710 2/20 0.60
SMN1; SMN2 Q16637 2/20 0.60
KDM4E B2RXH2 1/20 0.60
MEN1 O00255 1/20 0.60
MITF O75030 1/20 0.60
KMT2A Q03164 1/20 0.60
MTNR1A P48039 1/20 0.59
L3MBTL1 Q9Y468 1/20 0.56
OPRM1 P35372 4/20 0.54
GLA P06280 1/20 0.50
HTT P42858 1/20 0.50
LTB4R2 Q9NPC1 1/20 0.50
MAPK1 P28482 1/20 0.49
CHRM2 P08172 1/20 0.49
CHRM3 P20309 1/20 0.49
FNTA P49354 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2936216 0.92 OPRM1 (0.58) AGERNPC1ALDH1A1RAB9APAX8
SCHEMBL22387506 0.86 SLC6A2 (0.51) AGERNPC1ALDH1A1RAB9APAX8
SCHEMBL2814615 0.85 AGER (0.67) AGERNPC1ALDH1A1RAB9APAX8
SCHEMBL25073932 0.85 AGER (0.60) AGERNPC1ALDH1A1RAB9APAX8
SCHEMBL20857048 0.82 OPRM1 (0.56) AGEROPRM1CHRM2CHRM3LMNA
SCHEMBL17314167 0.81 SLC18A3 (0.57) AGERNPC1ALDH1A1RAB9APAX8
SCHEMBL23144528 0.81 SLC18A3 (0.54) AGERNPC1ALDH1A1RAB9APAX8
SCHEMBL17314168 0.81 SLC18A3 (0.57) AGERNPC1ALDH1A1RAB9APAX8
SCHEMBL17314169 0.81 SLC18A3 (0.57) AGERNPC1ALDH1A1RAB9APAX8
SCHEMBL21865386 0.79 TACR1 (0.47) AGERNPC1ALDH1A1RAB9APAX8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220387411-A1 TARGETED AUTOPHAGY CONJUGATES AND METHODS VULCAN BIO CORPORATION 2022-12-08 US disclosed
US-20220387411-A1 TARGETED AUTOPHAGY CONJUGATES AND METHODS VULCAN BIO CORPORATION 2022-12-08 US disclosed
CN-115151561-A Targeted autophagy conjugates and methods 前沿药品公司 2022-10-04 CN disclosed
EP-4034557-A1 TARGETED AUTOPHAGY CONJUGATES AND METHODS Frontier Medicines Corporation (US) 2022-08-03 EP disclosed
WO-2021061858-A1 TARGETED AUTOPHAGY CONJUGATES AND METHODS FRONTIER MEDICINES CORPORATION (US) 2021-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220387411-A1 TARGETED AUTOPHAGY CONJUGATES AND METHODS ATG7, BECN1, SQSTM1 AGER 1427/4885NPC1 48/4885ALDH1A1 3444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.